Arch Therapeutics, Inc. (ARTH) Research
Arch Therapeutics, Inc., operating alongside its affiliated companies, functions as a biotechnology firm within the United States. The organization focuses on developing and commercializing products derived from its unique AC5 self-assembling technology platform. These innovations are engineered to arrest bleeding, control fluid leakage, and assist in wound care during surgical interventions, following trauma, throughout interventional medical procedures, or in cases of disease. Its leading products, the AC5 advanced wound system and the AC5 topical hemostat, are specifically designed for application on the skin, proving effective for managing intricate chronic wounds or acute surgical injuries. The company was established in 2006 and is headquartered in Framingham, Massachusetts.
Market snapshot
- Symbol
- ARTH
- Price
- $0.00
- Day change
- +0.00%
- Market cap
- $444.0
- P/E ratio
- -0.00x
- 52-week range
- 0.0001-1.567
- Sector
- Healthcare
- Industry
- Biotechnology
Peer companies
Recent insider activity
- ABRAMS MICHAEL S — A-Award (20584 shares) on 2023-08-31
- ABRAMS MICHAEL S — P-Purchase (10292 shares) on 2023-08-31
- Norchi Terrence W — A-Award (13724 shares) on 2023-08-31
- Norchi Terrence W — P-Purchase (6862 shares) on 2023-08-31
- Hicks Laurence — A-Award (20584 shares) on 2023-08-31
Open Arch Therapeutics, Inc. (ARTH) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.